tetano
Editor, Senior Moderator
J Assoc Physicians India
. 2022 Dec;69(12):11-12.
Coronavirus Disease, Diabetes and Glucocorticoid a Terrible Trio for Invasive Mucormycosis: An Observational Study from Northwest Rajasthan
Hardeva Ram Nehara[SUP] 1 [/SUP], Sahdev Kumawat[SUP] 2 [/SUP], Jigyasa Gupta[SUP] 3 [/SUP], Gaurav Gupta[SUP] 4 [/SUP], Parmendra Sirohi[SUP] 5 [/SUP], Sunil Ih[SUP] 6 [/SUP], Balkishan Gupta[SUP] 5 [/SUP]
Affiliations
Abstract
Objective: This study aims to describe the epidemiology, predisposing factors, clinical manifestations, management, and outcome of post-COVID rhino-cerebralorbital mucormycosis.
Methods: This is a prospective observational study of patients with post-COVID RCOM conducted tertiary care hospital during May-June 2021.
Results: The mean age of patients was 49.58±15.12 years and majority (64.80%) were male. The majority of patients were rural, Hindu and illiterate. Diabetes was present 78.10% patients, glucocorticoids were required in 66.30%, and supplemental oxygen was used in 27.60% of patients. Most of the patients developed symptoms of RCOM within 15 days of COVID-19. Majority of patients (46.67%) had stage 3 disease and orbit was involved in 60% of patients. All patients received intravenous antifungal drugs and combined antifungal drugs and surgical debridement was performed in 77.10% patients. Predictor associated with poor outcome were RCOM stage 3c or above and qSOFA score ≥2 at presentation.
Conclusion: Diabetes and glucocorticoids are the most important risk factors for post-COVID RCOM. COVID-19 patients must be followed closely for 2-4 weeks to detect mucormycosis as earlier as possible. Antifungal drugs should be started immediately if clinico-radiological feature suggest RCOM before microbiological confirmation. Combined medical and surgical treatment significantly reduces mortality.
. 2022 Dec;69(12):11-12.
Coronavirus Disease, Diabetes and Glucocorticoid a Terrible Trio for Invasive Mucormycosis: An Observational Study from Northwest Rajasthan
Hardeva Ram Nehara[SUP] 1 [/SUP], Sahdev Kumawat[SUP] 2 [/SUP], Jigyasa Gupta[SUP] 3 [/SUP], Gaurav Gupta[SUP] 4 [/SUP], Parmendra Sirohi[SUP] 5 [/SUP], Sunil Ih[SUP] 6 [/SUP], Balkishan Gupta[SUP] 5 [/SUP]
Affiliations
- PMID: 35057586
Abstract
Objective: This study aims to describe the epidemiology, predisposing factors, clinical manifestations, management, and outcome of post-COVID rhino-cerebralorbital mucormycosis.
Methods: This is a prospective observational study of patients with post-COVID RCOM conducted tertiary care hospital during May-June 2021.
Results: The mean age of patients was 49.58±15.12 years and majority (64.80%) were male. The majority of patients were rural, Hindu and illiterate. Diabetes was present 78.10% patients, glucocorticoids were required in 66.30%, and supplemental oxygen was used in 27.60% of patients. Most of the patients developed symptoms of RCOM within 15 days of COVID-19. Majority of patients (46.67%) had stage 3 disease and orbit was involved in 60% of patients. All patients received intravenous antifungal drugs and combined antifungal drugs and surgical debridement was performed in 77.10% patients. Predictor associated with poor outcome were RCOM stage 3c or above and qSOFA score ≥2 at presentation.
Conclusion: Diabetes and glucocorticoids are the most important risk factors for post-COVID RCOM. COVID-19 patients must be followed closely for 2-4 weeks to detect mucormycosis as earlier as possible. Antifungal drugs should be started immediately if clinico-radiological feature suggest RCOM before microbiological confirmation. Combined medical and surgical treatment significantly reduces mortality.